Natera, Inc. (NASDAQ:NTRA) Shares Bought by Cerity Partners LLC

Cerity Partners LLC lifted its holdings in Natera, Inc. (NASDAQ:NTRA - Free Report) by 7.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 85,645 shares of the medical research company's stock after buying an additional 5,863 shares during the quarter. Cerity Partners LLC owned approximately 0.06% of Natera worth $12,111,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of NTRA. Steward Partners Investment Advisory LLC raised its holdings in shares of Natera by 1,328.0% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company's stock worth $57,000 after buying an additional 332 shares during the period. PNC Financial Services Group Inc. raised its holdings in shares of Natera by 6.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,951 shares of the medical research company's stock worth $467,000 after buying an additional 186 shares during the period. Daiwa Securities Group Inc. raised its holdings in shares of Natera by 18.8% in the fourth quarter. Daiwa Securities Group Inc. now owns 2,170 shares of the medical research company's stock worth $344,000 after buying an additional 344 shares during the period. HighTower Advisors LLC raised its holdings in shares of Natera by 9.9% in the fourth quarter. HighTower Advisors LLC now owns 11,342 shares of the medical research company's stock worth $1,795,000 after buying an additional 1,023 shares during the period. Finally, EverSource Wealth Advisors LLC raised its holdings in shares of Natera by 372.9% in the fourth quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock worth $52,000 after buying an additional 261 shares during the period. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Natera Price Performance

NASDAQ NTRA traded down $1.45 during midday trading on Wednesday, hitting $148.40. 1,537,929 shares of the company traded hands, compared to its average volume of 1,424,807. The company has a market cap of $20.26 billion, a PE ratio of -100.95 and a beta of 1.73. The company's 50-day simple moving average is $160.72 and its 200-day simple moving average is $158.26. Natera, Inc. has a 52 week low of $92.14 and a 52 week high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last announced its earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.09. The business had revenue of $501.83 million for the quarter, compared to analysts' expectations of $446.68 million. Natera had a negative return on equity of 18.29% and a negative net margin of 10.36%. The business's revenue for the quarter was up 36.5% on a year-over-year basis. During the same quarter last year, the firm earned ($0.56) EPS. On average, research analysts predict that Natera, Inc. will post -1.49 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on NTRA. Barclays increased their price target on Natera from $160.00 to $190.00 and gave the stock an "overweight" rating in a report on Friday, May 9th. Piper Sandler raised their price objective on Natera from $205.00 to $210.00 and gave the stock an "overweight" rating in a report on Thursday, May 15th. Wall Street Zen downgraded Natera from a "hold" rating to a "sell" rating in a report on Saturday, May 17th. Finally, UBS Group raised their price objective on Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a report on Friday, May 9th. One investment analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $184.63.

Insider Buying and Selling

In other news, Director Gail Boxer Marcus sold 4,299 shares of the firm's stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $167.36, for a total value of $719,480.64. Following the completion of the sale, the director owned 8,118 shares of the company's stock, valued at $1,358,628.48. This trade represents a 34.62% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Solomon Moshkevich sold 3,000 shares of the firm's stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $166.77, for a total value of $500,310.00. Following the completion of the sale, the insider directly owned 130,205 shares of the company's stock, valued at $21,714,287.85. The trade was a 2.25% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 53,272 shares of company stock worth $8,345,368 over the last quarter. Insiders own 7.60% of the company's stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.